LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Design Therapeutics Inc

Design Therapeutics Inc

Fechado

10.98 -0.27

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.98

Máximo

11.26

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -18M
EPS	-0.29
Funcionários	54
EBITDA	-1.5M -20M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+78.67% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	98M 898M
Abertura anterior	11.25
Fecho anterior	10.98

Design Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mai. de 2026, 23:46 UTC

Conversa de Mercado

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 de mai. de 2026, 23:42 UTC

Conversa de Mercado

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 de mai. de 2026, 23:11 UTC

Conversa de Mercado

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 de mai. de 2026, 22:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 de mai. de 2026, 22:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 de mai. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 de mai. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 de mai. de 2026, 22:11 UTC

Conversa de Mercado

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 de mai. de 2026, 22:04 UTC

Conversa de Mercado

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparação entre Pares

Variação de preço

Design Therapeutics Inc Previsão

Preço-alvo

By TipRanks

78.67% parte superior

Previsão para 12 meses

Média 19.6 USD 78.67%

Máximo 22 USD

Mínimo 15 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Design Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Design Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.